Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02067065
Other study ID # ColonPropo-01
Secondary ID
Status Completed
Phase N/A
First received February 16, 2014
Last updated October 8, 2015
Start date January 2014
Est. completion date August 2015

Study information

Verified date October 2015
Source Hospital Beatriz Ângelo
Contact n/a
Is FDA regulated No
Health authority Portugal: Data Protection Agency
Study type Interventional

Clinical Trial Summary

Propofol is the preferred sedation for colonoscopy. There is debate on the safety of the administration of propofol by non-anesthesiologists, despite moderate quality evidence that support its' use.

There is only one small trial of a direct comparison of propofol sedation by anesthesiologists versus non-anesthesiologists.

Our aim is to compare the incidence of sedation related adverse events, the procedural quality indicators, times (onset, recovery, discharge) and patient satisfaction between non-anesthesiologist administered propofol sedation (NAAP) sedation and anesthesiologist propofol sedation.

A randomized clinical trial with the incidence of sedation related minor adverse events as primary endpoint will be conducted. Secondary endpoints include procedure quality indicators, propofol dosage and patient satisfaction.

A sample size of 330 subjects (2 arms of 165 patients) will be needed in order to obtain 90% power and a 5% significance level to exclude a 15% difference (15 - 30%) in adverse events incidence, estimated from our pilot experience. The sample size was adjusted for a 2% cross-over rate.

Informed and consenting patients undergoing colonoscopy examinations will be randomly assigned to one of two arms. One group will be sedated by an anesthesiologist according to a protocol of propofol mono-sedation. The other group will be sedated with propofol boluses, according to the European Society of Gastrointestinal Endoscopy (ESGE) NAAP guideline, with a 3-man team consisting of one endoscopist, one endoscopy nurse and a sedation nurse, trained in NAAP and exclusively dedicated to sedation and patient monitoring.


Recruitment information / eligibility

Status Completed
Enrollment 277
Est. completion date August 2015
Est. primary completion date March 2015
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria:

- Referred for elective colonoscopy as outpatients

- Must be able to provide the informed consent

Exclusion Criteria:

- American Society of Anaesthesiologists (ASA) class >2

- Pregnant women

- Difficult airway predictors (more than 2 ou Mallampati >3)

- Allergy to propofol or its' components

- IV drugs abuse

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic


Intervention

Drug:
Non-anesthesiologist propofol sedation
Bolus propofol sedation administered according to non-anesthesiologist propofol sedation guidelines of the European Society of Gastrointestinal Endoscopy
Propofol sedation administered by an anesthesiologist
Propofol sedation by an anesthesiologist
Procedure:
Colonoscopy
Elective total colonoscopy with or without biopsies, polypectomies or mucosal resection, as clinically indicated

Locations

Country Name City State
Portugal Hospital Beatriz Ângelo Loures

Sponsors (1)

Lead Sponsor Collaborator
Hospital Beatriz Ângelo

Country where clinical trial is conducted

Portugal, 

References & Publications (2)

Dumonceau JM, Riphaus A, Aparicio JR, Beilenhoff U, Knape JT, Ortmann M, Paspatis G, Ponsioen CY, Racz I, Schreiber F, Vilmann P, Wehrmann T, Wientjes C, Walder B; NAAP Task Force Members. European Society of Gastrointestinal Endoscopy, European Society of Gastroenterology and Endoscopy Nurses and Associates, and the European Society of Anaesthesiology Guideline: Non-anesthesiologist administration of propofol for GI endoscopy. Endoscopy. 2010 Nov;42(11):960-74. doi: 10.1055/s-0030-1255728. Epub 2010 Nov 11. — View Citation

Dumonceau JM, Riphaus A, Beilenhoff U, Vilmann P, Hornslet P, Aparicio JR, Dinis-Ribeiro M, Giostra E, Ortmann M, Knape JT, Ladas S, Paspatis G, Ponsioen CY, Racz I, Wehrmann T, Walder B. European curriculum for sedation training in gastrointestinal endoscopy: position statement of the European Society of Gastrointestinal Endoscopy (ESGE) and European Society of Gastroenterology and Endoscopy Nurses and Associates (ESGENA). Endoscopy. 2013 Jun;45(6):496-504. doi: 10.1055/s-0033-1344142. Epub 2013 May 23. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Minor adverse events Minor adverse events as defined by the International Sedation Task Force, including peripheral O2 saturation between 75-90% for less than 60 seconds, apnea, airway obstruction, sedation failure, allergic reaction without anaphylaxis, convulsion, brady/tachycardia and hypo/hypertension (>25% change from baseline) During the sedation period Yes
Secondary Propofol dosage Total propofol dosage During the colonoscopy - an estimated mean time of 20 minutes No
Secondary Patient satisfaction A 10 point visual scale on pain Before discharge - estimated mean recovery time of 1 hour No
Secondary colonoscopy quality indicators Colonoscopy quality indicators: time to cecum, withdrawal time, adenoma detection rate During the procedure No
Secondary Patient satisfaction 2 A 5 point likert scale on patient satisfaction with the sedation Before discharge - estimated mean recovery time of 1 hour No
See also
  Status Clinical Trial Phase
Recruiting NCT05294107 - Intestinal Organoids N/A
Completed NCT02503696 - Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD) N/A
Completed NCT01427725 - Special Investigation of LipaCreon on Long-term Use in Patients With Pancreatic Exocrine Insufficiency
Completed NCT00210249 - Development of an Evaluation Method of Elderly Condition in Patient Receiving Chemotherapy Treatment
Active, not recruiting NCT05602935 - Efficacy and Safety of SOX Regimen Combined With Camrelizumab as Neoadjuvant Treatment in Locally Advanced Gastric Cancer: a Phase II, Single-arm Study Phase 2
Completed NCT03614039 - Effect of Probiotic and Smectite Gel on NAFLD N/A
Completed NCT03717298 - Evaluation of Ocoxin-Viusid® in Advanced Pancreatic Adenocarcinoma Phase 2
Recruiting NCT05322486 - Palliative Primary Tumor Resection in Minimally Symptomatic Patients With Colorectal Cancer and Synchronous Unresectable Metastases
Completed NCT02267681 - Opioid Effects on Cognitive Function Following Colonoscopy Phase 4
Terminated NCT02503631 - Stool Sample Collection Protocol for Development of Screening Test for Colorectal Cancer and Other Digestive Tract Cancers
Completed NCT01600209 - Exact CRC Screening Test: Stool Sample Collection Study to Support Assay Validation Testing N/A
Completed NCT01260168 - Multi-marker Stool Test for Detection of Colorectal Neoplasia: Marker Panel Selection and Technical Development Studies N/A
Active, not recruiting NCT01037049 - Optimum Timing for Surgery After Pre-operative Radiotherapy 6 vs 12 Weeks Phase 2
Completed NCT03656744 - A Study of HTD1801 in Adults With Nonalcoholic Steatohepatitis (NASH) and Type 2 Diabetes Mellitus (T2DM) Phase 2
Completed NCT01463319 - Warm Water and Unsedated Colonoscopy Phase 0
Terminated NCT00577772 - Transit Time and Bacterial Overgrowth Using SmartPill Capsule N/A
Suspended NCT00606788 - Therapy Study of Automated Protocolized vs. Physician-Directed Non-Protocolized Weaning N/A
Completed NCT04080843 - Anlotinib Hydrochloride Capsules Combined With CAPEOX in RAS and BRAF Wild-type mCRC Patients Phase 2
Recruiting NCT03776760 - Strategies for Hepatitis C Testing and Treatment in Aboriginal Communities That Lead to Elimination
Terminated NCT04644315 - A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors Phase 2